Stock Scorecard



Stock Summary for Harmony Biosciences Holdings Inc (HRMY) - $32.47 as of 11/6/2026 12:55:52 PM EST

Total Score

17 out of 30

Safety Score

57 out of 100

Currently on the following lists
None
Tim's Recommendation
Possible Buy

Growth List Algorithm Criteria for HRMY

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for HRMY

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for HRMY

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for HRMY

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for HRMY (57 out of 100)

Stock Price Rating (Max of 10) 8
Historical Stock Price Rating (Max of 10) 9
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 6
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 5
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 9
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for HRMY

HRMY Q3 Earnings Miss Estimates on Higher Costs Despite Wakix Growth 11/5/2026 5:42:00 PM
Earnings call transcript: Harmony Biosciences misses Q3 2026 profit view 11/5/2026 3:53:00 PM
Harmony Biosciences Misses As Royalty Costs Squeeze Margins And WAKIX Growth Cools, With February Patent Rulings Looming 11/4/2026 6:40:00 PM
Harmony Biosciences Q3 Earnings Call Highlights 11/4/2026 6:11:00 PM
Harmony Biosciences Plans CEO Transition for 2027 11/4/2026 5:40:00 PM
Harmony Biosciences Hldgs Q3 2026 Earnings Call Transcript 11/4/2026 3:40:00 PM
Q3 sales rose to $268.9M, but profit fell at Harmony Biosciences (HRMY). 11/4/2026 1:40:00 PM
Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings and Revenues Lag Estimates 11/4/2026 12:40:00 PM
Harmony Biosciences reports Q3 revenue of $269M, reaffirms guidance By Investing.com 11/4/2026 12:40:00 PM
Harmony Biosciences stock faces November 4 earnings catalyst 11/3/2026 12:05:00 AM

Financial Details for HRMY

Company Overview

Ticker HRMY
Company Name Harmony Biosciences Holdings Inc
Country USA
Description Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 9/30/2026
Next Earnings Date N/A

Stock Price History

Last Day Price 32.47
Price 4 Years Ago 55.10
Last Day Price Updated 11/6/2026 12:55:52 PM EST
Last Day Volume 1,477,534
Average Daily Volume 1,083,746
52-Week High 43.49
52-Week Low 25.90
Last Price to 52 Week Low 25.37%

Valuation Measures

Trailing PE 10.75
Industry PE 21.68
Sector PE 64.15
5-Year Average PE 13.91
Free Cash Flow Ratio 3.44
Industry Free Cash Flow Ratio 20.89
Sector Free Cash Flow Ratio 39.55
Current Ratio Most Recent Quarter 3.48
Total Cash Per Share 9.44
Book Value Per Share Most Recent Quarter 18.26
Price to Book Ratio 1.89
Industry Price to Book Ratio 11.10
Sector Price to Book Ratio 39.92
Price to Sales Ratio Twelve Trailing Months 1.93
Industry Price to Sales Ratio Twelve Trailing Months 14.47
Sector Price to Sales Ratio Twelve Trailing Months 22.17
Analyst Buy Ratings 5
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 58,723,000
Market Capitalization 1,906,735,810
Institutional Ownership 102.26%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY -6.90%
Annual Earnings Growth 9.07%
Reported EPS 12 Trailing Months 3.02
Reported EPS Past Year 2.07
Reported EPS Prior Year 3.35
Net Income Twelve Trailing Months 181,270,000
Net Income Past Year 158,687,000
Net Income Prior Year 145,493,000
Quarterly Revenue Growth YOY 12.30%
5-Year Revenue Growth 40.30%
Operating Margin Twelve Trailing Months 20.20%

Balance Sheet

Total Cash Most Recent Quarter 549,769,000
Total Cash Past Year 752,502,000
Total Cash Prior Year 453,001,000
Net Cash Position Most Recent Quarter 415,808,000
Net Cash Position Past Year 608,839,000
Long Term Debt Past Year 143,663,000
Long Term Debt Prior Year 163,016,000
Total Debt Most Recent Quarter 133,961,000
Equity to Debt Ratio Past Year 0.86
Equity to Debt Ratio Most Recent Quarter 0.88
Total Stockholder Equity Past Year 870,218,000
Total Stockholder Equity Prior Year 659,155,000
Total Stockholder Equity Most Recent Quarter 999,243,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 354,899,000
Free Cash Flow Per Share Twelve Trailing Months 6.04
Free Cash Flow Past Year 347,889,000
Free Cash Flow Prior Year 218,668,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.46
MACD Signal -0.63
20-Day Bollinger Lower Band 33.58
20-Day Bollinger Middle Band 38.28
20-Day Bollinger Upper Band 42.97
Beta 0.98
RSI 51.14
50-Day SMA 35.02
150-Day SMA 33.77
200-Day SMA 34.22

System

Modified 11/6/2026 11:42:28 PM EST